Evidence map›Paper›PMID 28246407›Full record

SynthesisScientific reports2017

ZEB1 regulates glioma stemness through LIF repression.

Lincoln A Edwards, Aiguo Li, Dror Berel, Mecca Madany, Nam-Ho Kim, Minzhi Liu, Mitch Hymowitz, Benjamin Uy, Rachel Jung, Minlin Xu and 5 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. ZEB1: New advances in fibrosis and cancer.Molecular and cellular biochemistry · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Advances in circular RNAs and their role in glioma (Review).International journal of oncology · 2020
    Article
  17. Article
  18. Article
  19. [Overexpression of leukemia inhibitory factor enhances chemotherapy tolerance of endometrial cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Lincoln A EdwardsDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Aiguo LiNeuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Dror BerelBiostatistics Core, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mecca MadanyDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nam-Ho KimDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Minzhi LiuDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mitch HymowitzDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Benjamin UyDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Rachel JungDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Minlin XuDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Keith L BlackDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Altan RentsendorjDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Xuemo FanPathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Wei ZhangNeuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
John S YuDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA. john.yu@cshs.org.
Cedars-Sinai Medical Center · USNational Cancer Institute · US

Funding

Bone marrow derived neural stem cell therapy for gliomaR01NS048959 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI YU, JOHN S · 2004 to 2014
$3.1M
NINDS NIH HHS R01 NS048959
6 · The paper itself

Abstract

The identification of a stem cell regulatory gene which is aberrantly expressed in glioma and associated with patient survival would increase the understanding of the role of glioma cancer stem cells (GCSCs) in the virulence of gliomas. Interrogating the genomes of over 4000 brain cancers we identified ZEB1 deletion in ~15% (grade II and III) and 50% of glioblastomas. Meta-analysis of ZEB1 copy number status in 2,988 cases of glioma revealed disruptive ZEB1 deletions associated with decreased survival. We identified ZEB1 binding sites within the LIF (stemness factor) promoter region, and demonstrate LIF repression by ZEB1. ZEB1 knockdown in GCSCs caused LIF induction commensurate with GCSC self-renewal and inhibition of differentiation. IFN-γ treatment to GCSCs induced ZEB1 expression, attenuating LIF activities. These findings implicate ZEB1 as a stem cell regulator in glioma which when deleted leads to increased stemness, tumorigenicity and shortened patient survival.

Indexed as

Gene Expression RegulationGene DeletionGene DosageGliomaHumansLeukemia Inhibitory FactorNeoplasm GradingProtein BindingRepressor ProteinsSurvival AnalysisZinc Finger E-box-Binding Homeobox 1Leukemia Inhibitory FactorLIF protein, humanRepressor ProteinsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID28246407
PMCPMC5427900
OpenAlexW2592517177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.